Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Alx Oncology Holdings (ALXO) EBITDA Margin (2019 - 2023)

Alx Oncology Holdings' EBITDA Margin history spans 4 years, with the latest figure at 21321.93% for Q4 2023.

  • For Q4 2023, EBITDA Margin fell 3526955.0% year-over-year to 21321.93%; the TTM value through Dec 2023 reached 2157.76%, down 5138677.0%, while the annual FY2025 figure was 1333.08%, 30474.0% down from the prior year.
  • EBITDA Margin for Q4 2023 was 21321.93% at Alx Oncology Holdings, down from 13625.32% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1834050.0% in Q3 2022 and bottomed at 21321.93% in Q4 2023.
  • The 4-year median for EBITDA Margin is 9886.29% (2023), against an average of 397251.8%.
  • The largest YoY upside for EBITDA Margin was -3526955bps in 2023 against a maximum downside of -182042468bps in 2023.
  • A 4-year view of EBITDA Margin shows it stood at 241.56% in 2019, then tumbled by -747bps to 2046.87% in 2020, then soared by 781bps to 13947.62% in 2022, then plummeted by -253bps to 21321.93% in 2023.
  • Per Business Quant, the three most recent readings for ALXO's EBITDA Margin are 21321.93% (Q4 2023), 13625.32% (Q3 2023), and 9886.29% (Q2 2023).